ASAP is excited to support Accelerating Medicines Partnership® in Parkinson's Disease and Related Disorders (AMP® PDRD), a public-private partnership that seeks to identify biomarkers that reliably discern #ParkinsonsDisease from other related neurodegenerative diseases. We look forward to witnessing the ways in which AMP® PDRD will accelerate the pace of discovery in Parkinson's disease research. Learn more: https://lnkd.in/ewdasqhB
Parkinson’s disease affects nearly one million people in the U.S. and 8.5 million worldwide. Early and accurate diagnosis is challenging due to similarities with other neurological disorders, and available treatments can only manage symptoms, not offer a cure. Today the FNIH is proud to announce the launch of the Accelerating Medicines Partnership® in Parkinson’s Disease and Related Disorders (AMP® PDRD). This public-private partnership aims to identify and validate biomarkers that will differentiate Parkinson’s disease from related disorders, leading to earlier diagnoses, more timely interventions, and better treatment options. Read the full press release here: https://lnkd.in/ewdasqhB National Institute of Neurological Disorders and Stroke (NINDS) | National Institute on Aging (NIA)| FDA | Aligning Science Across Parkinson’s | ASAP | C2N Diagnostics | CurePSP | Denali Therapeutics | GSK | Sanofi | The Michael J. Fox Foundation for Parkinson's Research #ParkinsonsDisease #Parkinsons #NeurologicalDisorders #FNIH #BridgestoBreakthroughs #AcceleratingMedicinesPartnership #PublicPrivatePartnership #AMP